Verrica
West Chester, United States · Biotechnology, Healthcare, Health Care · 78 employees
Verrica Pharmaceuticals Inc. is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. We believe there’s a better way to safely and effectively bring relief to patients, deliver peace of mind to parents and caregivers, and advance accessible therapies to prescribers and payers. We are focused on changing the narrative around skin diseases and
Funding history
- Funding Round — $50.0M — Dec 2025
- Funding Round — $20.0M — Feb 2018
- Funding Round — $5.0M — Dec 2017
- Funding Round — $2.4M — Dec 2015
Recent signals
- Feb 12, 2026: Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer
- Dec 10, 2025: Raised $50.0M
- Nov 23, 2025: SEC 8-K (1.01): On November 23, 2025, Verrica Pharmaceuticals, Inc. entered into two Securities Purchase Agreements to conduct a private placement transaction with institutional and accredited investors. The Company agreed to sell approximately 6.5 million shares of common stock along with pre-funded warrants for approximately 5.3 million shares and Series C warrants for around 2.9 million shares. This financing is intended to support the Company's ongoing operations and strategic initiatives. The move is significant as it provides the necessary capital for future growth, while also involving a considerable number of convertible instruments that could affect the Company's share structure.
- Mar 26, 2025: Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer
- Feb 21, 2018: Raised $20.0M
- Dec 22, 2017: Raised $5.0M
- Dec 17, 2015: Raised $2.4M
See plans & pricing → Track Verrica’s funding, hiring, and signals — with verified contacts — on Fundz.